Many commonly used drugs, with each causing changes that may be potentially lethal, can adversely affect the function of the heart. In addition some drugs have synergistic effects that can also damage cardiovascular tissues. The drug-related cardiotoxic effects of antineoplastic agents, psychotropic medications, heavy metals, substances of abuse, promotility agents, antihistamines, antimicrobials and antiarrhythmic agents are discussed. Hypersensitivity myocarditis is also discussed.
Commonly used drugs with individual results can, on occasion, have unexpected adverse effects on cardiac function. In patients on multiple drugs (polypharmacy), previously unknown synergistic effects can occur that can damage cardiac tissues. As more drugs are introduced to the market, these drugs effects and the effects of combinations of drugs must be carefully analysed and investigated prior to mass marketing. Unfortunately, sometimes these effects are not seen or reported until much later, after their introduction. Hence it is critical that all adverse drug reactions be reported to the appropriate national authorities (such as the Food and Drug Administration (FDA) in the USA). This review discusses common medications, which are known to be toxic to the heart, including those which cause direct damage to the myocardium or cause dysfunction in the conduction system. Broad drug classes discussed in this review are those known to have cardiotoxicity, and include antineoplastic agents, psychotropic medications, heavy metals, substances of abuse, promotility agents, antihistamines, antimicrobials and antiarrhythmic agents. Hypersensitivity myocarditis is also discussed. It is unfortunate that there are relatively few cases reporting the human pathology of many of these drugs.
ANTINEOPLASTIC AGENTS Antibodies Trastuzumab Introduction and clinical use
Trastuzumab is a monoclonal antibody, which binds to particular growth receptors (human epidermal growth factor 2, also termed HER2-Neu), whose downstream effects include intracellular metabolism and growth. 1 As a mutation in this receptor (HER-2 oncogene) has been found in 20-25% of patients with breast cancer, trastuzumab has been used to bind to these aberrant receptors and abate the downstream growth effect. This remains an important adjunct to management, as HER-2 active breast cancers are associated with decreased morbidity and mortality. 2 Though original animal studies did not detect any cardiotoxic effects, subsequent human studies identified an increased incidence of reduced left ventricular (LV) function, which at times can precipitate various signs and symptoms of congestive heart failure (CHF). Most often, it causes an asymptomatic decrease in ventricular function. A retrospective review of all patients enrolled in phase II and III clinical trials found that patients treated with trastuzumab were at increased risk of cardiac dysfunction. 3 Two recent meta-analyses of five randomised clinical trials (HERA, NSABP-31, NCCTGHN9831, BCIRG006 and FIN HER) evaluated the use of adjuvant trastuzumab for the treatment of breast cancer. Despite the fact that its use has been found to significantly reduce mortality, recurrence and metastasis (p,0.001), those treated with trastuzumab were at increased risk of developing CHF (RR = 7.6) and were found to have a decline in LV ejection fraction (RR = 2.09) compared to those not receiving adjuvant therapy. 4 
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Pathogenesis
The exact mechanism of cardiac myocyte damage is unclear. However, several animal studies have found that an alteration of the ratio of pro-and antiapoptotic effects may lead to mitochondrial dysfunction, and subsequently cell death. By exposing antierbB2 antibody to neonatal rat ventricular myocytes in vitro, Grazette et al found an increased expression of Bcl-2 (a pro-apoptotic molecule), a decrease in expression of Bcl-xS (an anti-apoptotic molecule), and an increase in BAX (which causes cytochrome c release and caspase activation). With these altered levels of proteins, mitochondrial dysfunction occurs and activates the mitochondrial apoptosis pathway. 6 It is believed that trastuzumab may cause cardiac myocyte apoptosis. The effect on cardiac myocytes has been found, in most instances, to be reversible and its effects independent of dosage. 1 
Pathological findings
Patients with cardiac toxicity secondary to trastuzumab may not have any histological findings at light microscopy. There is an absence of any visible structural changes. Non-specific changes have been seen at electron microscopy, including myocyte hypertrophy, pleomorphic mitochondria, interstitial fibrosis and focal vacuolar changes, all of which are, at least potentially, reversible. 7 Pathological analysis of a patient who died following trastuzumab therapy from ventricular fibrillation and cardiac arrest showed slight interstitial oedema at light microscopy and intracellular oedema, along with lipid droplets in myocyte cytoplasm. 8 
Anti-tumour antibiotics Anthracycline Introduction and clinical use
Anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin and valrubicin) are a group of antineoplastic drugs often used for hematopoietic and solid tumours (breast, uterine, ovarian and lung cancers). They are derived from a soil bacillus, the actinomycete Streptomyces. Long considered a potent antineoplastic agent, it has multiple mechanisms of action, including inhibition of DNA and RNA synthesis, inhibition of topoisomerase II enzyme which blocks DNA transcription and replication, and creation of free oxygen radicals, which can damage DNA and cell membranes.
Cardiotoxicity of anthracyclines has been recognised for over 40 years. 9 Three types of cardiotoxicity related to anthracycline use have been described: acute or subacute cardiotoxicity, which occurs during treatment; chronic cardiotoxicity, which causes a cardiomyopathy up to a year following treatment; and late-onset cardiotoxicity, which may manifest 5 years or more after initial management. 10 Though rare, acute or subacute cardiotoxicity may occur after one single dose. These patients have changes on their ECG, such as prolongation of the QT interval, and are predisposed to supraventricular, ventricular and junctional arrhythmias. 10 Chronic cardiotoxicity (often termed classic cardiomyopathy), is dose-dependent, and in most cases, cause signs and symptoms of congestive heart failure secondary to dilated cardiomyopathy. The symptoms typically occur 3 months following treatment, and generally occur less than one year post-treatment. The incidence of CHF, at a dose of 550 mg/m 2 body surface area is 7%, compared to 0.14% in patients receiving doses ,400 mg/m 2 . 11 Patients who present with ventricular dysfunction, CHF or arrhythmias following an asymptomatic period at least 1 year post-treatment are categorised as late-onset cardiotoxicity. 10 Patients have been known to present 3 or more years after cessation of anthracycline therapy.
Pathophysiology
Though multiple mechanisms of myocyte damage have been described, the most common hypotheses include the formation of free radicals and activation of intracellular ryanodine receptors which increases intracellular calcium levels. Both theories implicate direct myocyte death.
Superoxide and hydrogen peroxide were found to be raised in the sarcoplasmic reticulum and mitochondria in the rat heart, two areas that are subject to direct injury. 12 Further, in vitro studies have found that the addition of superoxide dismutase and tocopherol (a free radical scavenger) decreased the levels of freeoxygen radicals in myocardial cells exposed to anthracyclines. 13 14 Ryanodine receptors are found in the sarcoplasmic reticulum, and when activated, release calcium ions, which contribute to muscle contraction. The administration of anthracyclines has been implicated in the activation of these receptors, causing failure of the contractile elements. Multiple studies have found increased intracellular calcium with exposure of Adriamycin during in vitro experiments by increasing activity of the ryanodine receptor. 15 16 Increased release of calcium causes a net decrease of calcium availability, causing cardiac contractile dysfunction. 17 Other proposed mechanisms include alteration of expression of alpha-actin, myosin and troponin genes, dysfunctional myocardial adrenergic expression, and toxic metabolites derived from anthracyclines. 10 
Pathological findings
Pathological findings seen at light microscopy include vacuolation of myofibres, decreased size of muscle fibres (both suggesting myofibril loss), interstitial oedema and fibrosis. 18 The morphological changes seen at endomyocardial biopsy can be graded, based on the degree and extent of myocyte damage. 19 Electron microscopy shows loss of myofilaments, 10 and significant dilatation of the sarcoplasmic reticulum and probably also of the transverse tubule system 19 20 
Alkylating agents Cyclophosphamide and cisplatin
Introduction and clinical use
Alkylating agents, like cyclophosphamide, have been used to treat many malignancies including breast cancer, haematological malignancies, multiple myeloma, neuroblastoma, ovarian cancer and retinoblastoma. 21 First reported in patients receiving autologous bone marrow transplantation and high dose cyclophosphamide in 1972, 22 cyclophosphamide has been found to cause cardiotoxicity at higher doses during bone marrow transplantation. Total dosage exceeding 120 mg/kg has been found to cause changes on ECG after six courses. 23 These ECG changes include shortened QRS complexes, non-specific T wave and ST segment changes, tachyarrhythmias and complete heart block. 21 Diminished LV systolic function 5-16 days following the initiation of therapy was found in one study following the administration of doses exceeding 180 mg/kg over 4 days. Symptoms of CHF were found in 9 (28%) patients, while 6 (19%) patients developed pericardial tamponade, from acute pericarditis; only one of this cohort survived this complication. 24 Cisplatin is another chemotherapeutic agent that binds and induces cross-linking of DNA to trigger apoptosis in highly proliferative cells, including malignant cells. Its cardiotoxic effects include supraventricular tachycardia, bradycardia, changes in the ST-T segment, acute ischaemic events and ischaemic cardiomyopathy. 21 
Pathophysiology
The pathophysiology of cyclophosphamide-induced cardiotoxicity is not well understood. It is believed that direct endothelial damage from cyclophosphamide leads to leakage of plasma proteins (toxic metabolites and erythrocytes) into the interstitium. The breakdown of endothelial cells and the presence of these metabolites causes direct damage to the myocardium and capillary blood vessels, leading to oedema, intersitial haemorrhage and the formation of microthrombi, which further exacerbate myocardial damage. These effects are not dosedependent. 24 As the ventricular wall becomes oedematous and haemorrhagic, a reduction in LV diastolic function occurs, often leading to a restrictive cardiomyopathy. Haemorrhagic myocarditis may also occur following treatment with cyclophosphamide. 25 Reported as early as 1979, hypomagnesaemia has long been known to be one of the many toxic effects of cisplatin. 26 As diminished levels of magnesium in the serum may cause myocardial instability, it may predispose an individual to arrhythmias. Several case reports have described this phenomenon, as the patients developed an episode of asystole or atrial fibrillation, which recovered following magnesium replacement. 27 
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Pathological findings
In patients receiving cyclophosphamide as part of their chemotherapeutic regimen, pericardial light microscopy might Figure 2 (A-D) Explanted heart from a 48-year-old woman treated with Adriamycin for breast carcinoma. Orthotopic heart transplantation was performed 3 years after chemotherapy. The heart showed cardiomegaly (weight 280 g without the atria) and biventricular dilatation. (E) Explanted heart from a 48-year-old woman treated with Adriamycin for acute promyelocytic leukaemia, with orthotopic heart transplantation 7 months after chemotherapy. The myocardium in both the right ventricle (A) and left ventricle (B) appears stiff and darker than normal. Patchy areas of endocardial fibrosis are seen (asterisk). The tricuspid valve (TV) was incompetent and its annulus was dilated. The mitral valve (MV) can also be seen. At light microscopy, myofibre loss and fibrosis (arrows), as well as vacuolation of myofibres (arrowhead) can be seen in (C-D). Diffuse, severe interstitial fibrosis is seen. Transmission electron microscopy (E) shows a muscle fibre (M) with loss of myofibrils and a marked increase in interstitial collagen (asterisk). ((C) H&E, original magnification 620; (D) Movat pentachrome, original magnification 620; (E) original magnification 64600) reveal acute pericarditis, 25 and examination of the myocardium may demonstrate endothelial injury and haemorrhagic myocarditis. 24 Microthrombi composed of fibrin and platelets may also be found in the capillaries. 25 There are no pathological findings reported with cisplatin toxicity since its effects are reversible on treatment with magnesium.
Anti-metabolites 5-Fluorouracil
Introduction and clinical use 5-Fluoruracil (5-FU) is a nucleotide derivative (pyrimidine analogue) that incorporates itself into host DNA and RNA, and causes termination of the replicating strand. It has long been used to treat solid tumours (since 1957). 29 Since the first reported case of angina associated with its use in 1975, 30 multiple larger studies have reported cardiotoxic effects, in particular, ischaemic heart disease. It is now believed that 2-10% of patients treated with 5-FU will develop cardiotoxicity. 31 A large prospective clinical study evaluating the cardiotoxic effects of 5-FU in 367 patients receiving doses of 600-1000 mg/ m 2 /day found a variety of cardiac complications. Cardiac events occurred in 28 patients (7.6%), with onset of symptoms occurring shortly after initiation of treatment (mean = 3 days). Of these 28 patients, 18 (64%) developed anginal symptoms, 6 (21%) developed hypotension, 5 (18%) developed hypertension, 2 (7%) developed dyspnoea and 1 (4%) developed an arrhythmia. On discontinuation of 5-FU, 6 patients did not further develop cardiac symptoms, while the others experienced unstable angina, cardiovascular collapse, pulmonary oedema and death. ECG changes, including ST changes and T wave inversion (suggestive of ischaemia) was found in 65% of patients, and echocardiography showed cardiac hypokinesia. It is important to note that other chemotherapeutic agents such as cisplatin, mitomycin and folinic acid were also used. 32 Arrhythmias (atrial fibrillation, ventricular tachycardia and fibrillation), cardiogenic shock and sudden death have also been reported to occur weeks following completion of treatment with 5-FU. 21 
Pathophysiology
The exact mechanism of 5-FU toxicity has not been well established, but the main pathophysiological process is believed to be vasospasm, involving the coronary vessels, leading to ischaemia of the supplied myocardium. Vasospasm of the coronary arteries is typically seen with infusion of 5-FU. Though in vitro studies have been reported, very few in vivo experiments have demonstrated vasoconstriction. Measurement of brachial artery diameter in humans found significant vasoconstriction following infusion of 5-FU in 50% (n = 30) of patients, compared to 0% of patients receiving cisplatin/ carboplatin, anthracycline or cyclophosphamide. Identified risk factors for developing these complications include patients with a previous history of cardiovascular disease. 31 
Pathological findings
Microscopic findings have been well demonstrated in biopsy and autopsy specimens. Postmortem findings in one patient receiving both cisplatin and 5-FU who had developed a dilated cardiomyopathy and left-sided cardiac failure included interstitial oedema and intracytoplasmic vacuolisation of myocytes. There was no evidence of any inflammatory changes. 33 
PSYCHOTROPIC MEDICATIONS Lithium Introduction and clinical use
Lithium was first introduced to treat manic depressive illnesses in the 1960s, and after its successful use in patients with acute mania, reports of teratogenicity were reported in 1973. 34 Multiple registries were introduced and risk ratios as high as 400 times (compared to the general population) were reported. Congenital anomalies include a variety of cardiac anomalies, in particular Ebstein's anomaly. A more recent evaluation of four case-control studies found that the increased risk of cardiac anomalies in infants whose mothers took lithium in the first trimester was only 3.0 and 1.5.
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Despite these reassuring reports, cardiotoxicity of lithium has been implicated in the causation of dysrhythmias (sinus bradycardia, sinoatrial block, first-degree atrioventricular block and rarely complete heart block) with high doses in patients with underlying cardiac disease. 35 36 Often occurring in patients with chronic toxicity, cardiac effects occur in 20-30% of these patients. 35 There is no evidence that lithium causes prolongation of the QT interval. 37 
Pathophysiology
In high doses, lithium enters the myocytes, and replaces intracellular levels of potassium. Since at elevated levels it is not easily removed from the myocardial cells, it decreases spontaneous depolarisation of the sino-atrial node and decreases electrical conductivity through the atrioventricular node. 36 
Pathological findings
Gross examination of an infant heart with Ebstein's anomaly demonstrated displacement of the annulus of the tricuspid valve into the right ventricle. Not only is the anatomical location of the valve affected, the integrity of the valve leaflets (septal and posterior) is also compromised. Often the leaflets are adherent to the ventricular wall, leading to a large right atrium (atrialisation of the ventricle), and are unable to function normally, causing problems in both forward flow and regurgitation. Other findings include dilation of the resulting ''atrial tissue'', redundancy of the remaining anterior leaflet and dilation of the tricuspid annulus. 38 Other cardiac anomalies include an atrial septal defect (80-94% of patients), and less often, bicuspid or atretic aortic valves, pulmonary atresia, hypoplastic pulmonary artery, subaortic stenosis, mitral valve prolapse, ventricular septal defects and pulmonary stenosis. 38 
Tricyclic antidepressants Introduction and clinical use
Tricyclic antidepressants (TCAs) were one of the first antidepressant medications used in clinical practice, alongside monoamine oxide inhibitors. With the introduction of newer agents, such as the selective serotonin receptor inhibitors (SSRIs), and their known cardiotoxicity, they are less commonly used today. Since their introduction, not only have they been useful in the treatment of mood disorders, but they are also useful in the management of neuropathic pain, nocturnal enuresis, migraine, attention deficit hyperactive disorder, anxiety and smoking cessation.
TCAs cause orthostatic hypotension, conduction delay and antiarrhythmic disturbances. Those with underlying cardiac disease and taking cardiac medications are at increased risk of developing orthostatic hypotension, while those with no pre-existing cardiac disease are more prone to developing cardiac arrhythmias. 39 
Pathophysiology
TCAs have multiple effects on the cardiovascular system. First, they inhibit neurotransmitter uptake, which transiently causes hypertension and tachycardia. Following this state, a catecholamine-depleted state results, which leads to a decrease in blood pressure. In high doses, TCAs can also cause peripheral vasodilation due to alpha-adrenergic blockade. Lastly, and most importantly, TCAs block the sodium channels of the myocardium, and lead to hypotension, negative ionotropy and decreased cardiac output. The latter effect leads to dysrhythmias and alters cardiac conduction. One of the most lethal features is prolongation of the QT interval and widening of the QRS complex. 40 
Pathological findings
There are no specific morphological/pathological findings in patients with TCA toxicity.
Neuroleptics
Introduction and clinical use
Neuroleptics (antipsychotics) were first used for the treatment of severe psychotic disorders such as acute psychosis. The older neuroleptics were effective, but their side effect profile, including severe extrapyramidal symptoms, was not favourable. The next generation of neuroleptics, termed ''atypical antipsychotics'', are now used since they have a lower risk of adverse effects. Today, neuroleptics are used for management of a variety of psychiatric illnesses, including chronic psychotic disorders, manic and psychotic depressive syndromes, delirium and dementia. 41 ECG changes and sudden cardiac death after the use of neuroleptics, in particular thioridazine, were first reported in 1963. 42 Since then, multiple other neuroleptics have been reported to predispose patients to developing arrhythmias, secondary to prolongation of the QT interval. Typical antipsychotics that prolong the QT interval include chlorpromazine, haloperidol, perphenazine, sertindole, thioridazine, ziprasidone and doxepin. Atypical antipsychotics such as quetiapine and risperidone have also been implicated. 43 Risks for these complications include underlying cardiovascular disease, female sex, advanced age, electrolyte abnormalities (hypokalaemia and hypomagnesaemia) and other aetiologies that can also prolong the QT interval. 43 
Pathophysiology
Prolongation of the QT interval occurs by inhibition of the I Kr current (HERG channel), a channel important for cardiac repolarisation. Many studies have evaluated the class effects of these medications, and found a variability of degree of QT prolongation. Thioridazine, ziprasidone and quetiapine prolong the QT interval on average 35.8, 20.6 and 14.5 milliseconds respectively, while haloperidol and olanzapine minimally prolong the QT interval by 4.7 and 6.4 milliseconds respectively. 43 Though the risk of torsade de pointes has been reported with thioridazine and haloperidol, there are currently no reports of this complication with use of the atypical antipsychotics. 43 
Pathological findings
There are no specific morphological/pathological findings in patients with neuroleptic toxicity.
HEAVY METALS Arsenic trioxide Introduction and clinical use
Early reports of the cardiotoxic effects of arsenic were reported in patients exposed to pesticides, metallurgy, textiles, glass and paint. As arsenic trioxide is now used as treatment for refractory acute promyelocytic leukaemia (PML), its cardiotoxic effects have been documented. Its known cardiographic abnormalities include low flat T-wave, sinus tachycardia, prolonged QT intervals, atrioventricular blocks, multifocal ventricular tachycardia and ventricular fibrillation. 44 The most common change is prolongation of the QT interval, seen in 38% (n = 99) of patients treated with arsenic trioxide for advanced malignancies. 45 Arsenic-induced myocarditis has also been reported in the literature. 46 
Pathophysiology
Prolonged QT has been commonly reported in a large series studied by Barbey et al. They report only 1 case (n = 99) of torsade de pointes, 45 where rapid delayed rectifier potassium channel (I kr or HERG channel), if inhibited, is responsible for prolongation of the QT interval. Arsenic blocks this channel and inhibits repolarisation, causing a prolongation of the QT interval, and predisposes to the development of early after-depolarisations that can trigger torsade de pointes. As there is a low incidence of torsade de pointes in these patients, arsenic also activates an ATP-sensitive potassium channel (I k-ATP ), which promotes repolarisation and decreases arrhythmogenic potential. 47 Direct myocardial injury, believed to be related to oxidative damage, has also been found in patients exposed to arsenic. In mice models, administration of arsenic in cardiac myocytes caused a reduction in antioxidant compounds such as superoxide dismutase, catalase, glutathione-S-transferase, glutathione reductase and glutathione peroxidase. 48 
Pathological findings
Microscopic findings from toxic myocarditis include interstitial inflammatory infiltrates of polymorphonuclear leucocytes and erythrocytes, predominantly found in the perivascular areas, and surrounded by interstitial oedema. Perinuclear vacuolation is also seen within the myocardium. 49 
Iron
Introduction and clinical use
Iron is an important component of haem synthesis and oxygen carrying capacity in red blood cells. Humans predominantly absorb iron in the proximal small bowel from dietary sources. Since there is no mechanism for excretion, the body's iron levels are predominantly dependent on the regulation of iron reabsorption. 50 Various homoeostatic mechanisms exist to prevent toxic iron deposition in organs, such as an increased production of ferritin to offset the availability of active iron. Unfortunately, when iron levels surpass a particular level, this mechanism fails. 51 Iron toxicity may be primary or secondary. Hereditary haemochromatosis is an autosomal recessive genetically acquired condition where there is excess circulatory reabsorption leading to tissue iron overload, a type of liver cirrhosis, endocrinopathy and cardiomyopathy. 52 Premature deaths in this cohort are primarily due to cirrhosis. Secondary haemochromatosis occurs as a result of multiple transfusions for conditions such as thalassaemia. This group is at higher risk of CHF, predominantly diastolic prior to systolic failure.
Pathological findings
Gross examination of the heart suggests a red-brown looking heart that feels stiffer than usual. Light microscopy reveals significant granular, brown pigmentation in the perinuclear regions (considerably greater than that seen with the normal lipofuschin granules) in individual myocytes with H&E stain. Similar granules may be seen in vascular endothelial cells, and in mononuclear cells (macrophages) in the fibrotic interstitium. Special stains, such as Perl's or Prussian blue stain, cause these granules to stain a bright blue, and in fact show positive staining in areas away from the granules also (fig 3) . Electron microscopy of affected tissues shows enlarged mitochondria, with ruptured mitochondrial walls, disintegrated cristae and large coarse electron dense granules. 53 
SUBSTANCES OF ABUSE Alcohol Introduction and clinical use
The use of alcohol has long been known to cause damage to myocardium. Alcoholic cardiomyopathy is the most common cause, after ischaemic cardiomyopathy, of dilated cardiomyopathy. The incidence has been reported to be as high as 45% of autopsies in urban centres. 49 Despite this, recent evidence has found that light to moderate amounts of alcohol may be cardioprotective against the development of sudden cardiac death and coronary artery disease, though this still remains controversial. 54 The World Health Organization had previously indicated that ingested amounts above 20 g are harmful, but we now know that amounts exceeding 90-100 g/day can cause extensive damage to the myocardium. 54 Alcohol has been found to contribute to the development of various cardiac diseases, including acute arrhythmias and chronic dilated cardiomyopathy, often termed alcoholic cardiomyopathy. The pathophysiology of each is discussed below.
Pathophysiology
Arrhythmias, including atrial fibrillation, often called ''holiday heart'', are well known to occur following an episode of acute or binge drinking. Though less known, ventricular arrhythmias can also occur. Pochmalicki et al evaluated 41 patients by conducting an ECG, echocardiogram, signal average electrocardiogram, liver biopsy and serum tests four days after their last alcoholic drink. They found that patients with evidence of fatty liver also had an increased number of late ventricular potentials (LVPs). The presence of LVPs is a prognostic factor for the development of ventricular arrhythmias. The authors propose that delayed LVPs represent diseased myocardium that acts as an arrhythmogenic substrate. 55 Atrial fibrillation (AF) has long been known to occur following binge drinking, which is often benign and does not require long-term antiarrhythmic medication. AF occurs when there is an alteration of both sarcolemmal ion channel gene expression, and connexins that connect neighbouring myocytes. The most important alteration is a change in the L-type calcium current, which modifies the atrial refractory period, and interferes with organised atrial conduction, causing multiple atrial foci to initiate conduction. 56 The use of alcohol has been well known to inhibit cytosolic calcium by inhibiting the channels that give rise to the action potential, the release of stored calcium from the sarcoplasmic reticulum (SR), the process of calcium resequestration and the action of contractile units by calcium. 57 Long-term use of alcohol leads to alcoholic cardiomyopathy, and is one of the most common causes of dilated cardiomyopathy in North America. Though the mechanism for cardiomyopathy has not been completely determined, multiple mechanisms for myocyte damage have been proposed. As previously discussed, alcohol diminished calcium release from SR, altered Na + /K + ATPase activity, diminished mitochondrial activity and increased oxidative/free radical damage. 49 Another possibility is the direct effect that alcohol has on damaging cellular membranes. 49 
Pathological findings
The pathological findings are similar to other hearts with dilated cardiomyopathies from other aetiologies, and are therefore by themselves non-specific. Grossly, the heart may be 2-3 or more times heavier and larger than a normal heart, and its walls, especially the ventricles, are predominantly pale and thin. Thrombus may be found in these dilated areas. With dilation, the annulus of the mitral and tricuspid valves enlarges. Areas of fibrosis, viewed as paler areas, may be found along the endocardium and myocardium of both atria and ventricles.
Along with the gross findings, microscopic details are nonspecific for alcoholic cardiomyopathy. As the heart hypertrophies and dilates concomitantly, findings of both hypertrophy, such as enlarged myocytes, and dilation, including thin and elongated myocytes, are found. The endocardium often shows patchy thickening and fibrosis, and areas of interstitial fibrosis may be found, diffusely. 49 Ultrastructural findings include swollen and damaged SR within affected myocytes and few normal appearing mitochondria. 49 
Cocaine
Introduction and clinical use
Cocaine is derived from the Erythroxylon coca plant from South America, and was initially used as a local anaesthetic; it is now, however, the most commonly abused substance seen in patients in emergency departments due to its widespread use and variety of complications. 58 As it is a stimulant, users get a temporary sense of euphoria, with enhanced mental alertness and a diminished desire to eat or sleep.
Cocaine has two forms, the hydrochloride salt and the free base. Cocaine hydrochloride is a white crystalline powder, made by mixing the compound with hydrochloric acid, which forms granules. This form can be abused intranasally, orally or intravenously. The free base form, often termed ''crack'', is made by mixing the hydrochloride form with ammonia, followed by a solvent, and subsequently heating the solution, producing an ideal form to smoke. 58 As its addictive properties, as well as significant cardiovascular complications have been reported, it is now a controlled substance, and only indicated for topical anaesthetic use for ophthalmological and otolaryngeal procedures, as well as endoscopy for the respiratory and gastrointestinal tracts. 59 
Pathophysiology
Cocaine has been implicated in ischaemic events by multiple mechanisms. Well known for its role in coronary vasospasm, it also accelerates the production of atherosclerosis and increases platelet aggregation. The pathophysiology of vasospasm has been well documented. High levels of cocaine and its metabolites act as sympathomimetic agents, and disrupt endothelin-1 (a vasoconstrictor) and nitric oxide (a vasodilator), leading to cocaine-induced vasoconstriction. 60 Atherosclerosis is accelerated in cocaine users, and is found in 35-55% of patients undergoing angiography. 58 Continuous endothelial injury from cocaine use provides a nidus for atheroma formation. Following disruption of the endothelium, cocaine also induces platelet aggregation. 60 The formation of thrombus is also seen in cocaine users. Increased production of von Willebrand factor, plasminogen-activator inhibitor type I (PAI-1), and decreased levels of anti-thrombin III and activated protein C (APC) have been implicated in the thrombogenic effects of cocaine. 60 Since cocaine acts as a sympathomimetic, increased demand of the cardiac muscle also exacerbates the resulting ischaemic damage.
Cocaine has also been found to cause arrhythmias, including sinus tachycardia and bradycardia, supraventricular tachycardia, ventricular fibrillation and prolongation of the QT interval leading to torsade de pointes. 58 As cocaine is also a local anaesthetic, it inhibits sodium influx, which delays impulse conduction and, at times, gives rise to aberrant impulse conduction. Also, I Kr channels are blocked, further predisposing the heart to a variety of arrhythmias. 60 
Pathological findings
The pathological findings associated with chronic cocaine use vary, some not having any gross or microscopic changes, while others have extensive damage. Gross examination of the vessels may demonstrate no significant lesions or show atherosclerosis and thrombus, associated with cocaine's effects on increasing their severity. Cardiac ischaemic changes resulting in acute myocardial infarction in cocaine users are identical to noncocaine users, with a higher incidence of contraction band necrosis. 49 61 Though ischaemic events may lead to a dilated cardiomyopathy, there is inadequate evidence that cocaine cardiomyopathy is indeed a result of this. Microscopic examination of affected hearts demonstrated focal infiltrates of lymphocytic cells, interstitial fibrosis, hypertrophic myocytes and abnormal nuclei compared to dilated hearts from other aetiologies. 62 Cocaine myocarditis has been reported (fig 4) . Examination of 31 hearts of patients with cocaine-associated deaths detected myocarditis in 8 (40%) cases. The involved cells include a mixed infiltrate of mononuclear cells, including lymphocytes and macrophages. 63 
Methamphetamines
Introduction and clinical use
Methamphetamines are another class of sympathomimetic drug, synthesised in Japan in 1893 to combat fatigue and increase performance in soldiers in the military. 64 Currently, they are used therapeutically to treat attention-deficit hyperactivity disorder. These medications act to increase the release of monoamine neurotransmitters, which stimulate the central and peripheral nervous system. 65 If methamphetamines are smoked, they are highly addictive. Methamphetamines increase dopamine, norepinephrine and serotonin neurotransmission following immediate use. Unfortunately, its effects are highly addictive, and it is now a commonly abused substance. It is also known as ''speed'', ''crystal'', ''crank'', ''go'' and ''ice''. Acute ingestion results in a variety of symptoms, including instant euphoria, improved cognitive processing, excessive speech, excitability, agitation, aggressiveness, restlessness and repetitive tasks. 66 
Pathophysiology
With chronic use, persistently raised levels of monoamines cause an increase of blood pressure and heart rate. If this becomes chronic, it may lead to a variety of complications such as palpitations, arrhythmias, cardiomyopathy, ischaemic heart disease and cerebrovascular events. 66 A case-control study found an association between the development of dilated cardiomyopathy and symptoms of congestive heart failure. The measured ejection fraction between the two groups was 26% and 35% in the group using methamphetamines and the control group, respectively (p = 0.009). 67 The authors report that methamphetamines can cause cardiomyopathy via numerous mechanisms, which are similar to the effects of cocaine. Coronary vasospasm, tachycardia, hypertension, accelerated atherosclerosis and direct myocardial damage are thought to be a result of prolonged catecholamine stimulation. 67 The mechanism has been previously described with cocaine use. Acute myocardial infarction, with the same mechanism as cocaine, was seen in eight patients using crystal methamphetamine. 
Pathological findings
Though the pathological findings are not as well defined when compared to cocaine use, one study examined gross organ pathology in patients who died following methamphetamine. On gross examination, cardiomegaly and cardiac hypertrophy were found in 12% of hearts (n = 220). Atherosclerotic lesions, found in the coronary arteries as well as in the aorta, were also found in 39% of patients. 69 A case report of a man who died after injecting himself with methamphetamine revealed a variety of features on histopathological examination. Contraction band necrosis with patchy loss of myocytes was seen. In some areas, infiltration of neutrophils and small areas of haemorrhage were also seen. These findings were thought to have occurred after ischaemic changes following methamphetamine use. 70 
PROMOTILITY AGENTS Cisapride Introduction and clinical use
Cisapride is a serotonin 5-HT4 agonist, acting on the parasympathetic system, which stimulates the production and release of acetylcholine in the peripheral nervous system. As it works in the nervous system innervating the enteral system, it has been used to stimulate gastric motility in the small intestine, and thus has been an integral treatment modality for the management of gastro-oesophageal reflux. 71 Prior to its adverse effects, it was the first-line agent in the management of neonates who had feeding intolerance. 72 First reports of QT prolongation were published in 1996, after four people had died. Over three years, Wysowski et al reported 34 patients who developed torsade de pointes, and 23 patients who developed prolonged QT interval. Fifty-seven patients (56%) were taking other medications which inhibit cytochrome P450 enzymes (3A4), decreasing the metabolism of cisapride in the blood. 73 Following these reports, the FDA added a black box warning, both in 1995 and 1998, cautioning the use of cisapride in patients with medications which can increase serum levels of cisapride, as well as those with known QT prolongation. 71 
Pathophysiology
Prolongation of the QT interval in patients using cisapride occurs as a result of inhibition of the I KR channel, thus predisposing the patient to developing arrhythmias. The mechanism of action of this channel has previously been discussed in the arsenic trioxide section. 74 
Pathological findings
There are no reported morphological/pathological findings in patients taking cisapride.
ANTIHISTAMINES
Terfenadine, astemizole and norastemizole Introduction and clinical use
Diphenhydramine, one of the first antihistamines, though useful for the treatment of allergic disorders, had significant side effects, such as its sedative properties, anticholinergic effects, and diminished psychomotor function. This led to the development of non-sedating, second-generation antihistamines.
With 25 cases of torsade de pointes reported to the FDA following the use of terfenadine, there was much caution about its use. 75 Similar findings were reported for astemizole and norastemizole. 76 Terfenadine-containing drugs were removed from the US market in 1997, and the Canadian market in 1999. Astemizole and norastemizole were withdrawn from the market in 1998. Though not a class effect, other secondgeneration anti-histamines such as loratadine, cetirizine, azestaline and fexofenadine have not been found to cause prolonged QT intervals. 77 
Pathophysiology
Patients taking antihistamines developed prolongation of the QT interval and torsade de pointes as this drug inhibits the I Kr channel, increasing the risk of developing early after-depolarisations. 74 The mechanism of action of has previously been discussed.
Pathological findings
There are no reported pathological findings in patients taking terfenadine, astemizole or norastemizole.
ANTIMICROBIALS
Introduction and clinical use
Antimicrobial agents have been used to treat infections since the discovery of penicillin in 1941. Though the cardiotoxic effects of most drugs are found prior to mass marketing, other drugs, such as antibiotics have been added to the list of drugs that may cause QT prolongation, and should be used with caution in susceptible patients. Antibiotics such as macrolides (clarithromycin, erythromycin) and quinolones (ciprofloxacin, grepafloxacin), antivirals (lopinavir, nelfinavir, ritonavir, saquinavir), antifungals (azoles) and antiparasitic agents (chloroquine, pentamidine) are known to prolong the QT interval by affecting the HERG (K + ) channel and by altering drug levels by interacting with CYP P450 enzymes.
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Pathophysiology
Most antimicrobials cause prolonged QT interval and risk for torsade de pointes. The severity of QT prolongation is dependent on a variety of factors including gender, age, metabolic derangements, structural heart disease, genetic predisposition and drug-drug interactions with the cytochrome P450 enzymes. 79 The listed antimicrobial agents have been reported to affect the HERG channel (I Kr ), which regulates the outward flow of potassium from myocytes. As a result, potassium accumulates in the myocytes, and ventricular repolarisation is delayed, prolonging the QT interval.
As drug doses may also affect the QT interval, drugs that are substrates and/or inhibitors of cytochrome enzymes may also predispose the individual to develop torsade de pointes. In particular CYP3A4, and the variant alleles of CYP2C9/2C19 (poor metabolisers) have been reported to alter the clearance of drugs, and may contribute to the prolongation of the QT interval. 79 Macrolide antibiotics have been found to be a substrate and also to inhibit CYP3A4, and quinolones inhibit CYP1A2. 79 Protease inhibitors have been also found to be inhibitors of CYP3A4.
Pathological findings
There are no reported morphological/pathological findings in patients taking antimicrobials.
ANTIARRHYTHMIC DRUGS Introduction
Antiarrhythmic agents have been used to convert or maintain patients in normal sinus rhythm from arrhythmias of both atrial and ventricular origin. Class III antiarrhythmic agents can also be pro-arrhythmic, causing the rare complication of torsade de pointes by prolongation of the QT interval. The earliest drug found to cause this was quinine in 1918, when it was noted to cause syncope in patients. It was not until 30 years later that it was found to induce arrhythmias as well. 81 82 Sotalol, dofetilide and ibutilide have all been found to induce torsade de pointes in 2-8% of patients, whereas amiodarone induces this rhythm in less than 1% of patients. 83 84 Pathophysiology Each class III agent affects variable ion channels during cardiac repolarisation to cause QT prolongation. On average, sotalol and dofetilide prolong QTc interval by 45 and 55 msec respectively. 85 86 These two agents have also been found to induce early after-depolarisations, which can also induce torsade de pointes. Amiodarone, on average, prolongs the QTc by 70 msec, but rarely causes torsade de pointes. 87 Dofetilide and sotalol inhibit the I Kr (HERG channel), important in phase III of cardiac depolarisation. Ibutilide not only affects the HERG channel, but also has been found to activate I NaS (an inward sodium channel used in phase II). Amiodarone has been found to inhibit the potassium channels (I Kr , I Ks and I K1 ), which all are outward channels in phase III of cardiac depolarisation. 83 
Pathological findings
There are no reported morphological/pathological findings in patients taking class III antiarrhythmics. Amiodarone use, and especially use of large doses for prolonged periods, is known to induce significant morphological changes in multiple tissues including the pulmonary pneumocytes. However the same or similar changes have not been seen in the heart.
HYPERSENSITIVITY MYOCARDITIS Introduction
Hypersensitivity myocarditis is the most common form of heart disease in this category, and is initiated by a variety of drugs (table 1). Though its incidence is not definitely known, it can now be readily diagnosed by endomyocardial biopsy. 49 Patients often present with maculopapular pruritic rash after use of a known offending agent. Clinicians must be able to identify possible cases of hypersensitivity myocarditis in patients who present with symptoms of acute onset of CHF and with use of particular drugs.
Pathophysiology
For cases of hypersensitivity myocarditis, it is not the drug that initiates the reaction, but its metabolites, called haptens. A hapten is a low molecular weight inert molecule, which can only initiate an immune reaction when complexed to a larger molecule, often a protein. Once compounded together, they interact with T-and B-lymphocytes, and together produce antibodies. These antibodies subsequently stimulate cytokine production, and as a result, damage neighbouring normal cells. If a particular organ produces the hapten-bound protein, it is often that organ which gets damaged by the immunological response. 49 
Pathological findings
The pathological findings are identical and are independent of the drug involved. Grossly, if the myocarditis is severe, it can lead to biventricular dilatation, visible epicardial petechial haemorrhages, homogenous lesions of erythema or pallor in the myocardium and subendocardial haemorrhages. 49 The inflammatory infiltrate is composed predominantly of eosinophils, but invariably also includes lymphocytes, plasma cells and histiocytes, and can be found in focal areas, or diffusely across the myocardium with little or no evidence of myocardial necrosis, or replacement fibrosis 88 89 ( fig 5) . The inflammatory reaction can also affect blood vessels of all types-arteries, arterioles and veins-and lead to phlebitis or arteritis. 49 The extent of myocardial involvement does not correlate with clinical severity. 
CONCLUSIONS
There are many agents that cause adverse cardiac effects, some causing changes that are asymptomatic, and others, changes that can be life threatening. In order to prevent these changes, knowledge of each drug's effects and careful consideration of the use of each drug is integral to the understanding of the drug's effects for the clinician and for the safety of his/her patient. Contributing factors, such as the knowledge of each patient's underlying heart disease, other medications and their drug interactions, as well as metabolic disturbances must be considered prior to the initiation of any of these agents. For the pathologist, it is important to be aware of the pathological findings in each case from endomyocardial biopsy, and to be able to clinically correlate these findings to each patient. Take-home messages c Drug associated cardiotoxicities are not uncommon. They must be considered (at autopsy) in cases of sudden, unexpected death. c When drug toxicities are suspected, tissues should be taken for electron microscopy and a sample saved for future studies, since there is so little by way of good corroborative morphological data available on these patients. c The presence of eosinophils in the myocardium-interstitium, at endomyocardial biopsy or at autopsy, should alert the pathologist to the possibility of a hypersensitivity myocarditis. c With many new drugs coming into use, especially the new classes of antineoplastic agents (antibodies, eg HER2), tissue samples should be saved for ultrastructural studies.
